CAR-T therapy CLM-103 listed under the international nonproprietary name “venzukitagene autoleucel” (pINN List 134)

Selected for the Ministry of SMEs and Startups’ Startup Leap Technology Advancement Support Program

Phase 1 clinical trial results for glioblastoma presented orally at ESMO

Selected for the Full-Cycle Technology Development Project for Immune Cell Gene Therapies

Selected for the Ministry of SMEs and Startups’ “Startup Leap Package Support Program” Selected for the Osong High-Tech Promotion Project’s “Bio-Innovation Technology Regulatory Support Platform Construction Project”

Selected for the Ministry of Trade, Industry and Energy’s “Bio-Industry Technology Development Project”

CLM-103 Phase 1b/2 IND Approval CLM-201 Registered as a Patent in South Korea

CLM-202 Registered as a Patent in South Korea

GMP manufacturing facility approval from MFDS New Anticancer Antibody Drug CLM-101 Receives Approval for International Nonproprietary Name “Umikibart” (rINN List 92)

CLM-103 Selected for the ‘Bio Challenger’ program by MFDS

Acquired ‘Innobiz’ certification as an innovative company selected by MSS

Signed a business agreement for the development of innovative new anticancer drugs(HK Innoen)

CLM-103 Singapore patent registration

Certified as a youth-friendly small business selected by MOEL

Manufacturing Business Permission of advanced Biological Products

CLM-103 selected as a government project by Korea Drug Development Fund

Opening of Cell and Gene Therapy Manufacturing Facility (CGT Center)

CLM-103 Patent registration

Relocated Headquarters (Jeongneung-dong, Mediscience Park)

CLM-103 IND approved

Series B Inviting investment

CLM-103 China patent registration

CLM-103 Canada patent registration

CLM-103 US patent registration

CLM-103 Europe patent registration Signed joint R&D agreement with UNSW(The University of New South Wales), Australia

Signed a joint R&D business agreement with the Korea University's College of Medicine

Signed a business agreement for the development of anticancer immunotherapy (SG Medical)

CLM-103 Japan patent registration

CLM-103 Russia patent registration CLM-103 Australia patent registration

Acquired Venture Business certification

Acquired certification as a Company Affiliated Research Institute

YYB-101 Phase 2 approved Series A Inviting investment

Established CellabMED Co., Ltd. (spun off from Yooyoung Pharmaceuticals Bio Research Institute)

Completed YYB-101 Phase 1 Clinical Trial

Designated project for the Anti-Cancer Drug Development Group

Started Yooyoung Bio Research Institute